NCT01487902View on ClinicalTrials.gov

The Role of Androgen Deprivation Treatment (ADT) in Docetaxe-Prednisolone Chemotherapy for Castrate-Resistant Prostatic Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

October 31, 2013

Conditions
Castration-resistant Prostate Cancer
Interventions
DRUG

ADT

Luprolide 11.25 mg long-acting depo (Lucrin Depot PDS inj®) every 12 weeks SC wit Docetaxel-prednisolone (TAX327 regimen)

DRUG

No ADT

Docetaxel-prednisolone (TAX327 regimen) alone

Trial Locations (1)

138-736

RECRUITING

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER

NCT01487902 - The Role of Androgen Deprivation Treatment (ADT) in Docetaxe-Prednisolone Chemotherapy for Castrate-Resistant Prostatic Cancer | Biotech Hunter | Biotech Hunter